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A B S T R A C T
Background: Effects of sodium oxybate (SXB) on patients with narcolepsy with cataplexy (NC) or without
cataplexy (NWOC) have not been separately evaluated in clinical trials.
Methods: Retrospective analysis evaluated data from a phase 3, randomized, placebo-controlled trial of
SXB, modaﬁnil, and SXB +modaﬁnil versus placebo in adult NC patients (n = 95) or NWOC patients (n = 127).
NC patients were identiﬁed based on medical history, concomitant medications, and sleep-onset REM
periods on nocturnal polysomnography. The studied outcomes were changes from baseline at eight weeks
on the Epworth Sleepiness Scale (ESS), the Maintenance of Wakefulness Test (MWT), and the Clinical
Global Impression of Change (CGI-C).
Results: Among NC and NWOC patients, ESS improvement was signiﬁcantly greater with SXB and
SXB + modaﬁnil versus placebo. In NC patients, mean MWT sleep latency was signiﬁcantly increased with
SXB + modaﬁnil versus placebo. In NWOC patients, mean MWT sleep latency signiﬁcantly increased in
all groups versus placebo. Higher percentages of patients in the SXB and SXB + modaﬁnil groups were
“very much improved” or “much improved” on the CGI-C versus placebo in both NC and NWOC popu-
lations, although the difference did not reach statistical signiﬁcance in the NWOC populations. Adverse
events were consistent with previously-reported proﬁles for modaﬁnil and SXB. Nausea wasmore common
in the SXB and SXB + modaﬁnil groups. Dizziness and tremor were more common in the SXB + modaﬁnil
group only.
Conclusions: SXB alone and in combination with modaﬁnil improved subjective ratings of excessive sleepi-
ness and an objectivemeasure of the ability to stay awake to similar extents in NC patients andNWOCpatients.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Narcolepsy is a chronic neurologic condition that is character-
ized by a set of ﬁve core symptoms consisting of excessive daytime
sleepiness (EDS), cataplexy, hallucinations while falling asleep or
awakening (hypnagogic/hypnopompic hallucinations), sleep paral-
ysis, and disrupted nighttime sleep. While cataplexy is considered
pathognomonic for narcolepsy, it is present in approximately
60%–90% of patients [1]. Narcolepsy is subcategorized into two types:
type 1 narcolepsy is characterized by EDS and the presence of cata-
plexy or low hypocretin levels (observed in over 90% of type 1
narcolepsy patients), and type 2 narcolepsy is characterized by EDS
and the absence of cataplexy, with normal or unknown hypocretin
levels [2]. Both types of narcolepsy are characterized by symp-
toms and objective ﬁndings of EDS, which is present in all patients
with narcolepsy and is often the ﬁrst presenting symptom [2].
While there is increasing recognition that the pathophysiology
(eg, low hypocretin levels) and sleep architecture (eg, nocturnal
sleep-onset rapid-eye movement period) may vary between type
1 and type 2 narcolepsy [3–5], studies comparing the two types of
narcolepsy with regard to presentation, symptomatology, and re-
sponse to treatment are lacking. Clinically, type 1 narcolepsy is often
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distinguished from type 2 based on patient-reported cataplexy or
a medical history indicating cataplectic episodes [6].
Narcolepsy is associated with an economic burden resulting from
high healthcare resource utilization and costs [7–10] and indirect
costs associated with unemployment and lost productivity [7,9,10].
There is also a substantial patient burden arising from the greater
prevalence of comorbidities and higher odds for mortality relative
to those without narcolepsy [11–13] as well as signiﬁcant reduc-
tions in health-related quality of life relative to the general population
[9,14,15].
Treatment guidelines and best practice recommendations suggest
a symptomatic approach to management, with EDS and cataplexy
as the primary therapeutic targets [16–18]. Currently approved thera-
pies for the treatment of narcolepsy also target these symptoms,
and in particular, sodium oxybate (SXB) is approved to treat both
EDS and cataplexy associated with narcolepsy [19], while modaﬁnil
is approved to improve wakefulness in adult patients with exces-
sive sleepiness associated with narcolepsy [20]. There is, however,
a notable absence of any published literature on the effects of
modaﬁnil on cataplexy (frequency or severity). Meta-analyses have
substantiated the clinical trial eﬃcacy and safety proﬁle of these
two medications [21–23], and the effects of SXB administered in
combination with modaﬁnil have been suggested in one study to
be additive for the treatment of narcolepsy, as indicated by greater
combined effects on EDS than with either drug alone [24]. However,
it remains unknownwhether these drugs differ in eﬃcacy or adverse
events in the treatment of EDS in patients who have narcolepsy with
cataplexy versus those without. The inclusion of patients with and
without cataplexy in a clinical trial of SXB, modaﬁnil, and
SXB + modaﬁnil versus placebo provided an opportunity to retro-
spectively evaluate whether the presence or absence of cataplexy
impacts treatment response to drugs that treat EDS.
2. Methods
2.1. Design and patients
The data for this analysis were from a phase 3, randomized,
placebo-controlled trial that evaluated SXB alone and in combina-
tion with modaﬁnil for the treatment of adults with narcolepsy
(ClinicalTrials.gov identiﬁer NCT00066170) [24,25]. Methodology and
results for outcomes of excessive sleepiness, polysomnography, and
safety have been previously reported [24,25]. The study included
patients with narcolepsy, diagnosed using the second edition of the
International Classiﬁcation of Sleep Disorders [26], and who were
on a stable dose of modaﬁnil. The presence of cataplexy was not
an inclusion criterion, and thus the study included patients with
cataplexy (NC; n = 95) and without cataplexy (NWOC; n = 127). The
patients with NC were retrospectively identiﬁed based on a medical
history of cataplexy, a concomitant anticataplectic medication other
than SXB, and the presence of a sleep-onset rapid-eye movement
period on nocturnal polysomnography as described by Andlauer et al.
[4]; patients not classiﬁed as NC were classiﬁed as NWOC.
Patients on a stable dose of modaﬁnil were randomized to receive
either: SXB +modaﬁnil placebo (SXB group), SXB placebo +modaﬁnil
(modaﬁnil group), SXB + modaﬁnil, or SXB placebo + modaﬁnil
placebo (placebo group) for eight weeks. In this double-dummy trial
design, all patients were randomized to treatment groups that in-
cluded either SXB or SXB placebo, which was administered nightly
in two equally divided doses (at bedtime and 2.5–4 hours later);
patients received 6 g SXB or placebo equivalent for the initial four-
week period and then 9 g of the same nightly for the second four-
week period. Patients in the modaﬁnil group continued to receive
the samemodaﬁnil dosage (range: 200–600mg/day) that they were
receiving prior to randomization according to the protocol.
2.2. Outcomes
Eﬃcacy outcomes included the Epworth Sleepiness Scale (ESS)
[27] and the mean sleep latency on a four-period, 20-minute Main-
tenance of Wakefulness Test (MWT). Both the ESS and MWT were
administered at baseline and at Weeks 4 and 8 (end of treatment)
or early termination. Eﬃcacywas evaluated as the change from base-
line at Week 8 on both of these measures. Global change from the
clinician’s perspective was also evaluated using the Clinical Global
Impression of Change (CGI-C) [28], which is scored using a seven-
point Likert-type scale from 1 = “Very much improved” to 7 = “Very
much worse.” For the CGI-C, the percentages of patients who
achieved improvement at Week 8 were determined, with improve-
ment deﬁned as scores of “much improved” or “very much
improved.” Clinical Global Impression of Severity (CGI-S) was also
assessed only at baseline and was converted to numerical scores
based on an ordered six-point numerical scale ranging from one
(normal) to six (among the most extremely ill patients).
In addition to the eﬃcacy outcomes, the safety proﬁle, based on
the incidence of adverse events (AEs) was evaluated according to
the presence and absence of cataplexy.
2.3. Statistical analysis
Analyses were conducted on the intent-to-treat population,
deﬁned as patients who received one or more doses of double blind
trial medication and who had baseline and post-baseline eﬃcacy
measurements. Statistical evaluation of ESS and MWT, using a last
observation carried forward imputation approach, was performed
using equal slope analysis of covariance models adjusting for treat-
ment group, pooled site, and baseline ESS or sleep latency. The
primary pairwise comparisons of SXB alone and SXB + modaﬁnil
versus placebo were performed using Dunnett’s test and were con-
sidered interpretable if overall P < 0.05. Secondary pairwise
comparison of modaﬁnil alone versus placebo did not include an
adjustment for multiple comparisons. Analysis of CGI-C was based
on logistic regression with effects for treatment group and study
center and, similar to the other variables, pairwise comparisons of
SXB alone and SXB + modaﬁnil were considered interpretable if
overall P < 0.05, with comparisons considered signiﬁcant if P < 0.025
based on Bonferroni adjustment. Additionally, effect sizes versus
placebo were estimated for ESS and sleep MWT based on the dif-
ference between the means of the active treatment group and the
mean of the placebo divided by their pooled standard deviations
(Cohen’s d). Absolute values of effect sizes of 0.20 are generally con-
sidered small, 0.50 are moderate, and 0.80 are large [29].
All analyses were performed using SAS Version 9.3 (SAS Insti-
tute, Inc. Cary, NC).
3. Results
3.1. Demographics and disposition
As shown in Table 1, patients were predominantlyWhite (83.2%),
with a slightly higher percentage of males (54.7%), and amean (stan-
dard deviation [SD]) age of 39.2 (15.8) years. The population was
balanced across all treatment groups, and demographic character-
istics were generally similar between patients with NC and those
with NWOC.
However, patients with NC had signiﬁcantly higher baseline ESS
scores (15.1 versus 13.7; P = 0.035) and signiﬁcantly shorter mean
sleep latency times on the MWT (8.33 versus 12.07 minutes;
P < 0.001) than patients with NWOC. Additionally, clinician ratings
of severity at baseline indicated that NC patients had signiﬁcantly
more severe symptoms than patients with NWOC as rated on the
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CGI-S; mean (SD) scores of 4.0 (0.9) and 3.6 (0.9) for NC and NWOC,
respectively (P < 0.001) (data not shown).
3.2. Epworth Sleepiness Scale
Among patients with NC, themean change in ESS frommodaﬁnil-
treated baselinewas not statistically signiﬁcant atWeek 8 for patients
who stayed on the same dose of modaﬁnil or who switched from
modaﬁnil to SXB. However, the mean change in ESS from baseline
at Week 8 for patients who received SXB + modaﬁnil was signiﬁ-
cant (P = 0.002) and showed improvement. Relative to the placebo
group, which had a mean ESS increase of 0.8, the reductions in ESS
scores in both the SXB and SXB + modaﬁnil groups were signiﬁ-
cant, −2.9 (P = 0.011) and −3.8 (P = 0.002), respectively (Fig. 1). Effect
sizes relative to placebo were large for the SXB group (−0.80) and
for the SXB +modaﬁnil group (−1.15). Therewas no effect in the group
that stayed on modaﬁnil relative to placebo (0.7; P = 0.733, with a
negligible effect size of −0.03).
Among patients with NWOC, themean changes in ESS from base-
line at Week 8 for both the SXB group and for the SXB + modaﬁnil
groupwere signiﬁcant (both P < 0.001). Relative to the placebo group,
which had a mean ESS increase of 0.8, the reductions in ESS
scores were similar in the SXB group (−3.0; P = 0.021) and the
SXB + modaﬁnil group (−2.8; P = 0.015) (Fig. 1). Effect sizes rela-
tive to placebo were large, −0.89 for the SXB group and −0.99 for
SXB + modaﬁnil group. There was no effect in the group that stayed
on modaﬁnil (0.3; P = 0.775), which had an effect size of −0.175.
3.3. Maintenance of Wakefulness Test
On the MWT (Fig. 2), the mean sleep latency decreased by −2.58
minutes from baseline to Week 8 among the patients with NC who
were switched from modaﬁnil to placebo (the placebo group), in-
dicating that those patients stayed awake for a signiﬁcantly shorter
period of time (P < 0.05). In contrast, the MWT mean sleep latency
in the SXB + modaﬁnil group increased by 3.34 minutes from base-
line toWeek 8, indicating that those patients were able to stay awake
for a signiﬁcantly longer period of timewhen SXBwas added to their
dose of modaﬁnil (P < 0.05), and was also signiﬁcantly greater
Table 1
Baseline demographic and clinical characteristics.
Variable All patients Placebo SXB Modaﬁnil SXB + modaﬁnil P value
With cataplexy, n 95 32 14 26 23
Age, years, mean (SD) 39.2 (15.8) 41.3 (14.7) 35.1 (12.6) 37.1 (17.1) 41.3 (17.7) 0.417
Female, n (%) 43 (45.3) 19 (59.4) 6 (42.9) 10 (38.5) 8 (34.8) 0.263
Race, n (%) 0.426
Black 12 (12.6) 7 (21.9) 1 (7.1) 2 (7.7) 2 (8.7)
White 79 (83.2) 24 (75.0) 13 (92.9) 23 (88.5) 19 (82.6)
Other 4 (4.2) 1 (3.1) 0 1 (3.8) 2 (8.7)
ESS score, mean (SD) 15.1 (4.9) 15.0 (5.0) 14.1 (5.4) 14.4 (4.9) 16.5 (4.4) 0.409
MWT sleep latency, minutes, mean (SD) 8.33 (6.45) 9.57 (6.75) 9.47 (7.85) 7.52 (5.41) 6.82 (6.15) 0.354
Without cataplexy, n 127 23 36 37 31
Age, years, mean (SD) 38.1 (18.7) 40.7 (11.6) 35.1 (13.2) 40.1 (14.7) 37.2 (14.4) 0.482
Female, n (%) 72 (56.7) 12 (52.2) 18 (50.0) 21 (56.8) 21 (67.7) 0.500
Race, n (%) 0.218
Black 9 (7.1) 4 (17.4) 1 (2.8) 3 (8.1) 1 (3.2)
White 116 (91.3) 19 (82.6) 34 (94.4) 34 (91.9) 29 (93.5)
Other 2 (1.6) 0 1 (2.8) 0 1 (3.2)
ESS score, mean (SD) 13.7 (4.9) 12.7 (5.3) 14.5 (4.5) 13.8 (5.3) 13.3 (4.8) 0.600
MWT sleep latency, minutes, mean (SD) 12.07 (5.92) 9.96 (6.46) 12.02 (5.69) 12.56 (5.62) 13.10 (6.00) 0.251
ESS, Epworth Sleepiness Scale; MWT, Maintenance of Wakefulness Test; SD, standard deviation; SXB, sodium oxybate.
Fig. 1. Change from baseline in excessive daytime sleepiness assessed using the
Epworth Sleepiness Scale (ESS). The studywas of double-dummy design (seeMethods
for details). SE, standard error; SXB, sodium oxybate.
Fig. 2. Change from baseline in sleep latency assessed using theMaintenance ofWake-
fulness Test. The study was of double-dummy design (see Methods for details). SE,
standard error; SXB, sodium oxybate.
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compared with placebo (P < 0.001) resulting in a large effect size
of 1.19. There was a trend toward greater improvement in the SXB
group relative to placebo (0.90 minutes; P = 0.096), with a moder-
ate effect size of 0.76 (the lack of statistical signiﬁcance, even in the
presence of robust effect size, is likely due to the small number of
patients in the SXB group [n = 14] versus the modaﬁnil group
[n = 26]). The 0.40-minute increase observed in the modaﬁnil group
was signiﬁcant compared with placebo (P = 0.048), and resulted in
an effect size of 0.71.
Similar patterns were generally observed in patients with NWOC
(Fig. 2), with a signiﬁcant worsening from baseline toWeek 8 when
patients were switched from modaﬁnil to placebo, and improve-
ment when SXB was added to modaﬁnil (both P < 0.05). Relative to
the change in the placebo group (−2.90minutes), both the SXB group
and the SXB + modaﬁnil group had signiﬁcant increases in mean
MWT sleep latency time; 0.45 minutes in the SXB group (P = 0.007)
and 2.16minutes in the SXB +modaﬁnil group (P < 0.001), withmod-
erate and large effect sizes of 0.62 and 1.07, respectively. While the
mean MWT sleep latency from baseline to Week 8 numerically de-
creased in the modaﬁnil group, the difference relative to placebo
was signiﬁcantly smaller (P = 0.038) and resulted in a small effect
size of 0.37.
3.4. Clinical Global Impression of Change
Among the patients with NC, the percentage who were im-
proved on the CGI-C, deﬁned as ratings of “very much improved”
or “much improved,” was signiﬁcantly higher in the SXB group
(69.2%; P = 0.004) and the SXB + modaﬁnil group (59.1%; P = 0.001)
relative to placebo (18.8%) (Fig. 3). For patients with NC who stayed
on modaﬁnil, the percentage who were improved on the CGI-C
(20.0%) from baseline was similar to placebo (P = 0.934).
Although a numerically higher percentage of the NWOC pa-
tients who were treated with SXB (44.1% SXB) and combination
therapy (41.4%) were rated as “very much improved” or “much im-
proved” on CGI-C relative to placebo (28.6%), the differences did not
reach statistical signiﬁcance (Fig. 3). The percentage of NWOC pa-
tients who stayed on modaﬁnil who achieved these levels of
improvement (19.4%) was not signiﬁcantly different than placebo
(28.6%, P = 0.457).
3.5. Safety
Among the patients with NC, there was a signiﬁcant difference
across treatments in the incidence of any AEs (P = 0.040), which was
likely driven by the higher incidence of AEs among those treated
with SXB + modaﬁnil (Table 2). The incidence of AEs was similar
across treatments among patients with NWOC.
AEs were generally consistent with the proﬁles for modaﬁnil and
SXB [19,20]. The most common AEs, deﬁned as having an inci-
dence ≥5% in either of the cataplexy status groups, in the patients
with NC were headache (17.9%), nasopharyngitis (10.5%), nausea
(7.4%), dizziness (6.3%), and somnolence (6.3%) (Table 2). For nausea,
there was a signiﬁcant difference across treatments (P = 0.026), with
the highest incidence in the SXB group (21.4%). Similarly, the most
common AEs in patients with NWOC were nausea (15.7%), head-
ache (14.2%), dizziness (11.0%), vomiting (10.2%), tremor (7.1%),
arthralgia (6.3%), and somnolence (5.5%) (Table 2). Signiﬁcant dif-
ferences across treatments among NWOCwere observed for nausea,
Fig. 3. Treatment response assessed using the Clinical Global Impression of Change,
deﬁned as patients who achieved “much improved” or “very much improved.” The
study was of double-dummy design (see Methods for details). SXB, sodium oxybate.
Table 2
Adverse events (AEs) ≥ 5%.
AE Incidence, n (%) P value
All patients Placebo SXB Modaﬁnil SXB + modaﬁnil
With cataplexy, n 95 32 14 26 23
Any AE 56 (58.9) 20 (62.5) 8 (57.1) 10 (38.5) 18 (78.3) 0.040
Most common AEs*
Headache 17 (17.9) 7 (21.9) 2 (14.3) 2 (7.7) 6 (26.1) NS
Nasopharyngitis 10 (10.5) 3 (9.4) 4 (28.6) 2 (7.7) 1 (4.3) NS
Nausea 7 (7.4) 1 (3.1) 3 (21.4) 0 3 (13.0) 0.026
Dizziness 6 (6.3) 2 (6.3) 1 (7.1) 0 3 (13.0) NS
Somnolence 6 (6.3) 4 (12.5) 1 (7.1) 0 1 (4.3) NS
Without cataplexy, n 127 23 36 37 31
Any AE 93 (73.2) 19 (82.6) 24 (66.7) 24 (64.9) 26 (83.9) NS
Most common AEs*
Nausea 20 (15.7) 0 9 (25.0) 2 (5.4) 9 (29.0) 0.002
Headache 18 (14.2) 5 (21.7) 3 (8.3) 5 (13.5) 5 (16.1) NS
Dizziness 14 (11.0) 1 (4.3) 3 (8.3) 2 (5.4) 8 (25.8) 0.044
Vomiting 13 (10.2) 0 7 (19.4) 2 (5.4) 4 (12.9) NS
Tremor 9 (7.1) 0 2 (5.6) 0 7 (22.6) < 0.001
Arthralgia 8 (6.3) 1 (4.3) 4 (11.1) 3 (8.1) 0 NS
Somnolence 7 (5.5) 0 3 (8.3) 2 (5.4) 2 (6.5) NS
NS, not signiﬁcant; SXB, sodium oxybate.
* Deﬁned as occurring in ≥5% of all patients for either of the cataplexy status groups by the Medical Dictionary for Regulatory Activities preferred term.
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dizziness, and tremor, all of which were highest in the combina-
tion therapy treatment group.
4. Discussion
To our knowledge, this is the ﬁrst study to evaluate the effects
of SXB, or any narcolepsy treatment, on patients based on cata-
plexy status. In the current analysis, signiﬁcant differences were
observed at baseline in sleepiness and wakefulness between pa-
tients with NC and patients with NWOC. Patients with NC were
sleepier on the ESS and stayed awake for shorter periods of time
on the MWT. These differences have implications for differentially
characterizing type 1 and type 2 narcolepsy, especially consider-
ing that there is also increased recognition that these two narcolepsy
types may be objectively characterized by differences in sleep ar-
chitecture, CSF hypocretin levels, and HLA type [4,5].
The data reported here show that regardless of cataplexy status,
treatment with SXB alone and in combination with modaﬁnil re-
sulted in greater improvements relative to placebo in EDS as assessed
by the ESS, ability to stay awake as assessed bymean sleep latency on
theMWT, and global improvement in overall symptom status as rated
by the clinician. The effects were generally similar in the patients with
NC or with NWOC, and the combination of SXB + modaﬁnil consis-
tently resulted in improvements that were signiﬁcantly greater than
placebo and resulted in large effect sizes. Except for the change in ESS
score in the patients with NWOC, the combination of SXB +modaﬁnil
resulted in the greatest effect across outcomes and the effect sizeswere
consistently greater in that group than in any of the other groups. These
results further support previous observations that have led to the sug-
gestion that theremay be an additive effect of SXB andmodaﬁnilwhen
used together to treat EDS associatedwith narcolepsy [24]. This effect
appears to be independent of the presence of cataplexy.
Physician assessment of global improvement (CGI-C) showed nu-
merically greater percentages of patients who improved in the SXB
and SXB + modaﬁnil groups relative to placebo, also independent
of cataplexy status, although only in the patients with NC were the
differences statistically signiﬁcant. Theremay have also been a greater
placebo effect on CGI-C in the NWOC group. While categorization
of patients by NC or NWOC status was based on reasonable infor-
mation, full information about cataplexy was not available and thus
some patients may have been misclassiﬁed. In this regard, the pres-
ence of a sleep-onset rapid-eye movement period on nocturnal
polysomnography was one of the criteria for identifying NC pa-
tients. While a speciﬁcity of 82% for this criterion has been reported
in patients who have been diagnosed only on the basis of multi-
ple sleep latency test results, the speciﬁcity is as high as 99% in
patients who have documented low hypocretin levels, clear cata-
plexy, and HLA-DQB1*06:02 positivity, and it is likely that some of
the patients in this study had been diagnosed on the basis of these
assessments [4]. Nevertheless, it is possible that a small percent-
age of patients with NCmay have beenmisclassiﬁed as patients with
NWOC. This potential misclassiﬁcation is not expected to substan-
tially impact the current analysis since the likelihood of this is low.
Additionally, differences in baseline levels of subjective sleepiness
and objective ability to remain awake suggest that cataplexy status
was largely accurately identiﬁed.
It should be noted that since all subjects had been previously
treated with modaﬁnil, the interpretability of the results in the
modaﬁnil only treatment group may be limited. Additionally, it is
possible that patients who enrolled in this study may not have been
adequately treated by modaﬁnil alone.
5. Conclusions
In patients with narcolepsy, treatment with SXB alone and in
combination with modaﬁnil resulted in signiﬁcantly greater
improvements in EDS and wakefulness relative to placebo regard-
less of cataplexy status. The effects of SXB combined with modaﬁnil
on these outcomes were greater than either drug alone regardless
of cataplexy status, suggesting additive therapeutic effects of the
two drugs. Further evaluation of differences between these popu-
lations, and the implications for treatment is warranted.
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